THE Co-Occurrence of Jak2/Calr-Positive Myeloproliferative Disorder and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib.: Dual Myeloid Disorder Treated with Two Drug Association. (2025). Mediterranean Journal of Hematology and Infectious Diseases, 17(1), e2025023. https://doi.org/10.4084/MJHID.2025.023